Post-transplant pure red cell aplasia (PRCA) is a rare complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with ABO incompatibility.In most cases, this condition resolves without any treatment.However, in some patients, PRCA can persist for a long time, worsening the quality of life and somatic status.There is currently no consensus on the treatment of PRCA: previously used therapeutic options have limited application in the post-transplant period and low pathogenetic validity.In this article, we present a series of clinical cases of PRCA treatment with daratumumab, a monoclonal IgG1k anti-CD38 antibody.
No takes yet. Share an insight, caveat, or question.
Tsvirko et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: